Although atrial fibrillation (AF) is a well-known risk factor for embolic stroke in hypertrophic cardiomyopathy (HCM), there is a paucity of information derived from HCM patients who have experienced embolic stroke. From 141 consecutive HCM patients who had been hospitalized between 2000 and 2018, the clinical characteristics and management of 86 patients with AF were analyzed retrospectively. The incidence of embolic stroke was 36% (n=31 patients). The median (interquartile range) age of embolic stroke was younger in male than female HCM patients (71 [64-80] vs. 83 [77-87] years, respectively; P=0.009). The prevalence of paroxysmal AF (74%) was significantly higher than that of chronic AF (26%) in 31 patients with embolic stroke (P=0.007). The CHADS score in patients with embolic stroke was not particularly useful in predicting the occurrence of embolic stroke. One-third of HCM patients with AF developed embolic stroke, and male HCM patients were younger at the time of the embolic stroke than female HCM patients. The prevalence of paroxysmal AF was significantly higher than that of chronic AF in patients with AF and embolic stroke. Early introduction of anticoagulation therapy is recommended at the first documentation of paroxysmal AF.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099667 | PMC |
| http://dx.doi.org/10.1253/circrep.CR-20-0101 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of Carotid Plaques with High-risk Features in Embolic Stroke of Undetermined Source: Systematic Review and Meta-Analysis.
Int J Stroke
January 2025
Stroke Unit, Careggi University Hospital, Florence, Italy.
Introduction: Recent evidence suggests a possible role of non-stenotic carotid atherosclerotic plaques in the aetiology of embolic stroke of undetermined source (ESUS).
Methods: We conducted a systematic review and meta-analysis of prevalence and characteristics of non-stenotic carotid plaques (NSP) with high-risk features (complicated NSP) in internal carotid artery in unilateral ESUS in the anterior circulation. We searched Medline and Ovid-Embase databases.
Corrigendum to "Blockage of p38MAPK in astrocytes alleviates brain damage in a mouse model of embolic stroke through the CX43/AQP4 axis" [J Stroke Cerebrovasc Dis. 2024 Dec;33(12):108085/Article Number: YJSCD_JSCVD-D-24-00861].
J Stroke Cerebrovasc Dis
January 2025
Department of Neurology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi Province, PR China; Institute of Neuroscience, Nanchang University, Nanchang 330031, Jiangxi Province, PR China; Jiangxi Provincial Clinical Medical Research Center for Neurological Disorders, Nanchang 330031, Jiangxi Province, PR China. Electronic address:
Spontaneous echo contrast in the left atrial appendage is linked to a higher risk of thromboembolic events and mortality in patients with atrial fibrillation.
Int J Cardiol Heart Vasc
February 2025
Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
Background: Cardioversion, a rhythm control treatment for atrial fibrillation (AF), requires ruling out cardiac embolic sources, often originating from the left atrial appendage (LAA). Transesophageal echocardiography (TEE) is used for LAA evaluation, but it is invasive and not widely available. This study aimed to identify cardiovascular risk factors linked to LAA abnormalities and predictors of thromboembolic events and all-cause mortality.
View Article and Find Full Text PDFEmbolic Stroke in a Patient With Left Atrial Myxoma.
JACC Case Rep
December 2024
Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
We present a case of a patient with a left atrial myxoma who presented with an ischemic stroke. Her cardiac myxoma had an irregular contour and was highly mobile, both features that have been associated with a greater risk of thromboembolism. She was treated with prompt surgical resection.
View Article and Find Full Text PDFTwo-year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA-AF Asia registry.
J Arrhythm
February 2025
Global Specialty Medical Affairs Daiichi Sankyo, Inc. New York City NewYork USA.
Background: The non-vitamin K oral anticoagulant (NOAC), edoxaban, is approved for stroke prevention in patients with atrial fibrillation (AF) in many Asian countries. Nonetheless, data on its long-term effectiveness and safety in routine clinical practice are limited in Taiwan.
Methods: The Global ETNA-AF (Edoxaban Treatment in routiNe clinical prActice) registry is an observational study that integrates data of AF patients receiving edoxaban from multiple regional registries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!